Literature DB >> 24361676

Doxorubicin, DNA torsion, and chromatin dynamics.

Fan Yang1, Sheila S Teves1, Christopher J Kemp2, Steven Henikoff3.   

Abstract

Doxorubicin is one of the most important anti-cancer chemotherapeutic drugs, being widely used for the treatment of solid tumors and acute leukemias. The action of doxorubicin and other anthracycline drugs has been intensively investigated during the last several decades, but the mechanisms that have been proposed for cell killing remain disparate and controversial. In this review, we examine the proposed models for doxorubicin action from the perspective of the chromatin landscape, which is altered in many types of cancer due to recurrent mutations in chromatin modifiers. We highlight recent evidence for effects of anthracyclines on DNA torsion and chromatin dynamics that may underlie basic mechanisms of doxorubicin-mediated cell death and suggest new therapeutic strategies for cancer treatment.
Copyright © 2013 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anthracycline; Cancer; Chemotherapy; Chromatin dynamics; DNA torsion; Doxorubicin

Mesh:

Substances:

Year:  2013        PMID: 24361676      PMCID: PMC3927826          DOI: 10.1016/j.bbcan.2013.12.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  79 in total

1.  Targeting Histone Demethylases: A New Avenue for the Fight against Cancer.

Authors:  Dante Rotili; Antonello Mai
Journal:  Genes Cancer       Date:  2011-06

2.  Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.

Authors:  A Di Marco; M Gaetani; B Scarpinato
Journal:  Cancer Chemother Rep       Date:  1969-02

3.  Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin.

Authors:  J H Doroshow; T W Synold; G Somlo; S A Akman; E Gajewski
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

4.  Increase of ceramide in adriamycin-induced HL-60 cell apoptosis: detection by a novel anti-ceramide antibody.

Authors:  Mamoru Kawase; Mitsumasa Watanabe; Tadakazu Kondo; Takeshi Yabu; Yoshimitsu Taguchi; Hisanori Umehara; Takashi Uchiyama; Koji Mizuno; Toshiro Okazaki
Journal:  Biochim Biophys Acta       Date:  2002-10-10

5.  Ceramide reduction and transcriptional up-regulation of glucosylceramide synthase through doxorubicin-activated Sp1 in drug-resistant HL-60/ADR cells.

Authors:  Yoshikazu Uchida; Mitsuru Itoh; Yoshimitsu Taguchi; Syohei Yamaoka; Hisanori Umehara; Shin-Ichi Ichikawa; Yoshio Hirabayashi; Walter M Holleran; Toshiro Okazaki
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

6.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

Authors:  Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh
Journal:  Nat Med       Date:  2012-10-28       Impact factor: 53.440

7.  Site and sequence specificity of the daunomycin-DNA interaction.

Authors:  J B Chaires; K R Fox; J E Herrera; M Britt; M J Waring
Journal:  Biochemistry       Date:  1987-12-15       Impact factor: 3.162

8.  Epigenetic silencing of antiviral genes renders clones of Huh-7 cells permissive for hepatitis C virus replication.

Authors:  Qiuyue Chen; Bray Denard; Hua Huang; Jin Ye
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

9.  Mechanisms of chromosome banding. IX. Are variations in DNA base composition adequate to account for quinacrine, Hoechst 33258 and daunomycin banding?

Authors:  D E Comings; M E Drets
Journal:  Chromosoma       Date:  1976-07-08       Impact factor: 4.316

10.  Transcription-induced nucleosome 'splitting': an underlying structure for DNase I sensitive chromatin.

Authors:  M S Lee; W T Garrard
Journal:  EMBO J       Date:  1991-03       Impact factor: 11.598

View more
  163 in total

1.  Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors.

Authors:  Marjorie Carlson; Adrienne L Watson; Leah Anderson; David A Largaespada; Paolo P Provenzano
Journal:  J Biomed Opt       Date:  2017-11       Impact factor: 3.170

Review 2.  DNA repair pathways and their roles in drug resistance for lung adenocarcinoma.

Authors:  Altan Kara; Aykut Özgür; Sinem Nalbantoğlu; Abdullah Karadağ
Journal:  Mol Biol Rep       Date:  2021-04-15       Impact factor: 2.316

Review 3.  Chemoresistance and targeting of growth factors/cytokines signalling pathways: towards the development of effective therapeutic strategy for endometrial cancer.

Authors:  Fengjun Guo; Haina Zhang; Zanhui Jia; Manhua Cui; Jingyan Tian
Journal:  Am J Cancer Res       Date:  2018-07-01       Impact factor: 6.166

4.  Patterns of Early p21 Dynamics Determine Proliferation-Senescence Cell Fate after Chemotherapy.

Authors:  Chien-Hsiang Hsu; Steven J Altschuler; Lani F Wu
Journal:  Cell       Date:  2019-06-13       Impact factor: 41.582

5.  Loss of Krüppel-like factor 6 cripples podocyte mitochondrial function.

Authors:  Jeffrey B Kopp
Journal:  J Clin Invest       Date:  2015-02-17       Impact factor: 14.808

Review 6.  Hematopoietic Stem Cells: Normal Versus Malignant.

Authors:  Dustin Carroll; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2017-12-20       Impact factor: 8.401

7.  DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

Authors:  Olga A Guryanova; Kaitlyn Shank; Barbara Spitzer; Luisa Luciani; Richard P Koche; Francine E Garrett-Bakelman; Chezi Ganzel; Benjamin H Durham; Abhinita Mohanty; Gregor Hoermann; Sharon A Rivera; Alan G Chramiec; Elodie Pronier; Lennart Bastian; Matthew D Keller; Daniel Tovbin; Evangelia Loizou; Abby R Weinstein; Adriana Rodriguez Gonzalez; Yen K Lieu; Jacob M Rowe; Friederike Pastore; Anna Sophia McKenney; Andrei V Krivtsov; Wolfgang R Sperr; Justin R Cross; Christopher E Mason; Martin S Tallman; Maria E Arcila; Omar Abdel-Wahab; Scott A Armstrong; Stefan Kubicek; Philipp B Staber; Mithat Gönen; Elisabeth M Paietta; Ari M Melnick; Stephen D Nimer; Siddhartha Mukherjee; Ross L Levine
Journal:  Nat Med       Date:  2016-11-14       Impact factor: 53.440

8.  Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53.

Authors:  Min-Chi Yang; Ru-Wei Lin; Shih-Bo Huang; Shin-Yuan Huang; Wen-Jie Chen; Shiaw Wang; Yi-Ren Hong; Chihuei Wang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

9.  ALDH2 attenuates Dox-induced cardiotoxicity by inhibiting cardiac apoptosis and oxidative stress.

Authors:  Yawen Gao; Yan Xu; Songwen Hua; Shenghua Zhou; Kangkai Wang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 10.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.